The activity of purine analogs against Leishmania tropica in human monocytederived macrophages in vitro was determined. Formycin B, formycin A, formycin B and A monophosphate, and formycin A triphosphate all had 50% effective doses of 0.02 to 0.04 ,uM and eliminated 90%o of organisms at cO.5 ,uM. Allopurinol ribonucleoside was much less active: the 50% effective dose was 76 to 190 ,uM, and 90o of organisms were not eliminated at the highest dose tested (190 ,uM). 7-Deazainosine had a low 50% effective dose (0.2 ,uM), but only 80% of organisms were eliminated at 4 ,uM. Thio derivatives were as active as or less active than the parent compounds. These data suggest that certain inosine analogs are much more active than others against macrophage-contained Leishmania spp. such as are found in human lesions. However, because toxicity to the human macrophage hosts generally paralleled antileishmanial activity, the more active compounds might also be more toxic to human cells. The activity of 3-deazaguanosine (50% effective dose, 3.6 ,uM) in this model suggests that guanosine derivatives may have potential as antileishmanial agents.
The need for orally administrable, nontoxic antileishmanial agents has led to investigation of the antileishmanial activity of hypoxanthine and inosine analogs such as allopurinol, allopurinol ribonucleoside, and formycin B. In vitro, these agents are at least partially active against promastigotes and against amastigotes within macrophages, a clinically comparable model (2-4, 6, 10, 13) . In vivo, allopurinol is active against mucous leishmaniasis in Aotus monkeys (15) , and formycin B is active against visceral disease in hamsters (6; J. D. Berman, C. Keenan, S. Lamb, W. Hanson, and V. Waits, Exp. Parasitol., in press). Allopurinol is presently in trial against human visceral disease (9). In vitro biochemical studies have shown that the antileishmanial activity of these agents is due to metabolism of the drugs into analogs of inosine and adenosine nucleotides by the organisms (2, 6, (12) (13) (14) . Inhibition of guanosine nucleotide utilization may also be important for antileishmanial activity since mycophenolic acid, an inhibitor of guanosine monophosphate synthesis from inosine monophosphate, inhibits amastigote multiplication in vitro (4) .
A systematic investigation of the antileishmanial activity of purine analogs has not been reported. In the present work we determined and compared the activity of inosine, adenosine, and guanosine analogs against Leishmania amastigotes within human macrophages in vitro. This model is one in which clinically employed agents are active (5) and in which hypoxanthine metabolism is comparable to that of cells in general (4).
MATERIALS AND METHODS
Exposure of infected macrophages to purine analogs. Human macrophage cultures were derived from the monocytes of the peripheral blood of normal human volunteers by methods previously described (5) . After being infected with amastigotes of Leishmania tropica WR 401 (NIH 173), infected macrophage cultures in 1.0 ml of culture medium were exposed to a constant dose of a purine analog for 6 days. The culture medium used was RPMI-1640 (GIBCO Laboratories, Grand Island, N.Y.) containing 10%o heat-inactivated fetal calf serum (GIBCO Laboratories), penicillin (50 U/ml), and streptomycin (50 ,ug/ml). After 6 days, the number of amastigotes per 100 macrophages in control (non-drugtreated) cultures and experimental cultures was determined by counting 100 to 200 Giemsa-stained macrophages in each culture. The ED5o for 7-deazainosine was low (0.2 ,uM), but this analog eliminated only 80% of organisms at the highest nontoxic concentration (4 ,uM) ( Table 1 ). The thio derivative of 7-deazainosine was both less active against Leishmania and less toxic to macrophages than 7-deazainosine itself (Table 1) .
3-Deazaguanosine demonstrated an ED50 of 3.6 ,uM. The ED50 of 3-deazaguanine was greater than 134 ,uM; the ED50 for 3-deazaadenosine was greater than 72 ,uM (Table 1) . DISCUSSION Formycin B, formycin A, formycin B monophosphate, formycin A monophosphate, and formycin A triphosphate were the most active agents tested in vitro against L. tropica-infected human macrophages and had favorable therapeutic-toxic ratios. The apparent mechanism of action of formycin B is that it is metabolized to formycin B monophosphate, formycin A monophosphate, and formycin A triphosphate by the organisms, which then incorporate the triphosphate into RNA (12, 14) . Such metabolism exposes the organisms to potentially toxic formycin A nucleotides and formycin A containing RNA. Since formycin A is generally metabolized by cells to formycin A nucleotides, it is reasonable that both nucleosides display antileishmanial activity. The similarity of the activities suggests that in this model phosphorylation and amination of formycin B is as efficient as phosphorylation of formycin A. The antileishmanial activity of the formycin nucleotides might seem surprising since these phosphates should not be able to pass through macrophage membranes to attack the organisms. However, The percentage of macrophage-contained Leishmania spp. surviving exposure to several doses of a purine analog was determined in two to five experiments for each analog. The number of organisms per 100 macrophages in non-drug-treated controls was 805 ± 224 (n = 25). Formycin B or allopurinol was used as a positive control in each experiment. For compounds 1 through 5, for which the dose-response curves were steep, EDMxs were calculated for each experiment, and the means of these calculated values are listed with the ranges in parentheses. For compounds 6 through 15, for which the dose-response curves were relatively flat, the ED50s were estimated by inspection of the data. For compounds for which doses higher than the ED50s were tested, the dose that eliminated 90%o of organisms (.90%o effective dose) in all experiments is listed. ANTIMICROB. AGENTS CHEMOTHER. macrophage plasma membranes have an externally directed S'-nucleotidase active against adenosine S'-m0nophosphate (8) , and the formycin 5'-phosphates may be cleaved to the corresponding formycin nucleosides by this enzyme.
The similar anilehmanial activity of allopurinol to thiopurinol and of allopurinol ribonucleoside to thiopurinl ribonucleoside in this moel confirms the data from infected tumor macrophages (11 
